DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma
Latest Information Update: 13 Jun 2025
At a glance
- Drugs DT 2216 (Primary) ; Irinotecan (Primary)
- Indications Carcinoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Most Recent Events
- 05 Jun 2025 Planned initiation date (estimated date of first participant enrollment) changed from 20 Jun 2025 to 21 Feb 2026.
- 05 Jun 2025 Status changed from not yet recruiting to recruiting.
- 26 Mar 2025 Planned initiation date changed from 20 Mar 2025 to 20 Jun 2025.